Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth. The most common side effects include nerve damage, acne, vomiting, headache, low blood sugar, diarrhea, and liver inflammation. It is in the nitroimidazole class of medications.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - 프레토마니드 (ko)
- Pretomanid (en)
- PA-824 (ru)
|
rdfs:comment
| - 프레토마니드(Pretomanid)는 새로운 화학 물질로 nitroimidazooxazines라고 알려진 일종의 화합물의 구성원이다. Pretomanid는 새롭고 빠르게 작용하며 저렴한 결핵 의약품의 발견과 개발에 전념하는 비영리단체인 TB 얼라이언스(https://en.wikipedia.org/wiki/TB_Alliance" rel="mw:ExtLink" data-linkid="105" class="cx-link" title="TB Alliance">TB Alliance)에 의해 임상검사를 받았고 개발되었다. 미국 식품의약관리청 (FDA)은 2019년 8월 14일에 약물 내성 결핵 (highly drug resistant TB) 치료를 위해 이 약을 승인했다. (ko)
- PA-824 (претоманид) — бициклический , противотуберкулезный препарат. Одобрен для применения: США (2019). Разработан . Обладает активностью против Mycobacterium tuberculosis, при этом действует одновременно как ингибитор роста клеточной стенки (подобно изониазиду), и как дыхательный яд (подобно цианидам). Показано наличие противотуберкулёзной активности в доклинических испытаниях in vitro на клинических мультирезистентных изолятах Mycobacterium tuberculosis и in vivo на моделях туберкулёза мышей и морских свинок. Пороговая токсическая доза в доклинических исследованиях на мышах оценена как свыше 1000 мг/кг при однократном пероральном введении. (ru)
- Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth. The most common side effects include nerve damage, acne, vomiting, headache, low blood sugar, diarrhea, and liver inflammation. It is in the nitroimidazole class of medications. (en)
|
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
ATC suffix
| |
ATC prefix
| |
c
| |
CAS number
| |
ChEMBL
| |
ChemSpiderID
| |
DrugBank
| |
F
| |
H
| |
IUPAC name
| |
KEGG
| |
legal US
| |
MedlinePlus
| |
n
| |
O
| |
PubChem
| |
routes of administration
| |
SMILES
| - [O-] [N+]c1cn2C[C@@H]OCc3ccccc3 (en)
|
StdInChI
| |
StdInChIKey
| - ZLHZLMOSPGACSZ-NSHDSACASA-N (en)
|
synonyms
| |
tradename
| |
UNII
| |
has abstract
| - Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth. The most common side effects include nerve damage, acne, vomiting, headache, low blood sugar, diarrhea, and liver inflammation. It is in the nitroimidazole class of medications. Pretomanid was approved for medical use in the United States in August 2019, and in the European Union in July 2020. Pretomanid was developed by TB Alliance. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
- 프레토마니드(Pretomanid)는 새로운 화학 물질로 nitroimidazooxazines라고 알려진 일종의 화합물의 구성원이다. Pretomanid는 새롭고 빠르게 작용하며 저렴한 결핵 의약품의 발견과 개발에 전념하는 비영리단체인 TB 얼라이언스(https://en.wikipedia.org/wiki/TB_Alliance" rel="mw:ExtLink" data-linkid="105" class="cx-link" title="TB Alliance">TB Alliance)에 의해 임상검사를 받았고 개발되었다. 미국 식품의약관리청 (FDA)은 2019년 8월 14일에 약물 내성 결핵 (highly drug resistant TB) 치료를 위해 이 약을 승인했다. (ko)
- PA-824 (претоманид) — бициклический , противотуберкулезный препарат. Одобрен для применения: США (2019). Разработан . Обладает активностью против Mycobacterium tuberculosis, при этом действует одновременно как ингибитор роста клеточной стенки (подобно изониазиду), и как дыхательный яд (подобно цианидам). Показано наличие противотуберкулёзной активности в доклинических испытаниях in vitro на клинических мультирезистентных изолятах Mycobacterium tuberculosis и in vivo на моделях туберкулёза мышей и морских свинок. Пороговая токсическая доза в доклинических исследованиях на мышах оценена как свыше 1000 мг/кг при однократном пероральном введении. (ru)
|
DailyMedID
| |
legal EU
| |
gold:hypernym
| |